We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Read MoreHide Full Article
Puma Biotechnology, Inc. (PBYI - Free Report) announced that positive results from a randomized phase II study (I-SPY 2 – Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) on neratinib for the neoadjuvant treatment of breast cancer were published in the New England Journal of Medicine. The company’s shares were up 5.5% on the news.
The study, a collaborative effort among academic investigators, was conducted in women with newly diagnosed stage 2 or higher (tumor size at least 2.5 cm) breast cancer to evaluate whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy. The primary endpoint of the study was pathological complete response (pCR) in the breast and the lymph nodes at the time of surgery.
Results showed that treatment with the neratinib-containing regimen (neratinib plus paclitaxel followed by Adriamycin and Cytoxan) in HER2-positive patients (including those who were either hormone receptor-positive or negative) resulted in an estimated pCR rate of 39.4% compared with the control arm of 22.8%. On the safety front, the most frequently observed severe adverse event in the study was diarrhea.
We are encouraged by the phase II study results. Per the company’s press release, the I-SPY 2 data represents the first clinical data on neratinib in the neoadjuvant treatment of breast cancer and recommends that the combination of paclitaxel plus neratinib holds potent activity for the treatment of HER2-positive breast cancer and a subset of patients with HER2-negative breast cancer.
Puma Biotech expects to report data from its ongoing studies on the candidate through 2016.
We remind investors that Puma Biotech had announced last month that it has submitted a regulatory application in the EU seeking approval for neratinib. The company is looking to get neratinib approved for the extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with Roche Holding AG’s (RHHBY - Free Report) Herceptin (trastuzumab)-based adjuvant therapy.
Meanwhile, Puma Biotech also plans to seek FDA approval for neratinib shortly.
Given that Puma Biotech has no approved product in its portfolio at the moment and neratinib is its lead pipeline candidate, we expect investor focus to remain on updates pertaining to its development.
Puma Biotech is a Zacks Rank #4 (Sell) stock. A couple of better-ranked stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and Pfizer Inc. (PFE - Free Report) . While Innoviva sports a Zacks Rank #1 (Strong Buy), Pfizer carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Puma Biotechnology, Inc. (PBYI - Free Report) announced that positive results from a randomized phase II study (I-SPY 2 – Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) on neratinib for the neoadjuvant treatment of breast cancer were published in the New England Journal of Medicine. The company’s shares were up 5.5% on the news.
The study, a collaborative effort among academic investigators, was conducted in women with newly diagnosed stage 2 or higher (tumor size at least 2.5 cm) breast cancer to evaluate whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy. The primary endpoint of the study was pathological complete response (pCR) in the breast and the lymph nodes at the time of surgery.
Results showed that treatment with the neratinib-containing regimen (neratinib plus paclitaxel followed by Adriamycin and Cytoxan) in HER2-positive patients (including those who were either hormone receptor-positive or negative) resulted in an estimated pCR rate of 39.4% compared with the control arm of 22.8%. On the safety front, the most frequently observed severe adverse event in the study was diarrhea.
PUMA BIOTECHNLG Price
PUMA BIOTECHNLG Price | PUMA BIOTECHNLG Quote
We are encouraged by the phase II study results. Per the company’s press release, the I-SPY 2 data represents the first clinical data on neratinib in the neoadjuvant treatment of breast cancer and recommends that the combination of paclitaxel plus neratinib holds potent activity for the treatment of HER2-positive breast cancer and a subset of patients with HER2-negative breast cancer.
Puma Biotech expects to report data from its ongoing studies on the candidate through 2016.
We remind investors that Puma Biotech had announced last month that it has submitted a regulatory application in the EU seeking approval for neratinib. The company is looking to get neratinib approved for the extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with Roche Holding AG’s (RHHBY - Free Report) Herceptin (trastuzumab)-based adjuvant therapy.
Meanwhile, Puma Biotech also plans to seek FDA approval for neratinib shortly.
Given that Puma Biotech has no approved product in its portfolio at the moment and neratinib is its lead pipeline candidate, we expect investor focus to remain on updates pertaining to its development.
Puma Biotech is a Zacks Rank #4 (Sell) stock. A couple of better-ranked stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and Pfizer Inc. (PFE - Free Report) . While Innoviva sports a Zacks Rank #1 (Strong Buy), Pfizer carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>